ENTA
Price
$11.05
Change
-$0.41 (-3.58%)
Updated
Oct 10, 04:59 PM (EDT)
Capitalization
330.65M
38 days until earnings call
ORKA
Price
$24.47
Change
-$1.08 (-4.23%)
Updated
Oct 10, 04:59 PM (EDT)
Capitalization
1.09B
Interact to see
Advertisement

ENTA vs ORKA

Header iconENTA vs ORKA Comparison
Open Charts ENTA vs ORKABanner chart's image
Enanta Pharmaceuticals
Price$11.05
Change-$0.41 (-3.58%)
Volume$6.18K
Capitalization330.65M
Oruka Therapeutics
Price$24.47
Change-$1.08 (-4.23%)
Volume$9.58K
Capitalization1.09B
ENTA vs ORKA Comparison Chart in %
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORKA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. ORKA commentary
Oct 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and ORKA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 11, 2025
Stock price -- (ENTA: $11.46 vs. ORKA: $25.55)
Brand notoriety: ENTA and ORKA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 49% vs. ORKA: 320%
Market capitalization -- ENTA: $330.65M vs. ORKA: $1.09B
ENTA [@Biotechnology] is valued at $330.65M. ORKA’s [@Biotechnology] market capitalization is $1.09B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.04B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileORKA’s FA Score has 1 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • ORKA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ENTA and ORKA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 6 TA indicator(s) are bullish while ORKA’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 6 bullish, 4 bearish.
  • ORKA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than ORKA.

Price Growth

ENTA (@Biotechnology) experienced а +10.94% price change this week, while ORKA (@Biotechnology) price change was +33.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.98%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +83.18%.

Reported Earning Dates

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+3.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORKA($1.09B) has a higher market cap than ENTA($331M). ENTA YTD gains are higher at: 99.304 vs. ORKA (31.769). ORKA has more cash in the bank: 328M vs. ENTA (204M). ORKA has less debt than ENTA: ORKA (2.33M) vs ENTA (58M).
ENTAORKAENTA / ORKA
Capitalization331M1.09B30%
EBITDA-82.41MN/A-
Gain YTD99.30431.769313%
P/E RatioN/AN/A-
Revenue64.8MN/A-
Total Cash204M328M62%
Total Debt58M2.33M2,494%
FUNDAMENTALS RATINGS
ENTA vs ORKA: Fundamental Ratings
ENTA
ORKA
OUTLOOK RATING
1..100
8524
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORKA's Valuation (5) in the null industry is significantly better than the same rating for ENTA (99) in the Biotechnology industry. This means that ORKA’s stock grew significantly faster than ENTA’s over the last 12 months.

ORKA's Profit vs Risk Rating (100) in the null industry is in the same range as ENTA (100) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as ORKA (100) in the null industry. This means that ENTA’s stock grew similarly to ORKA’s over the last 12 months.

ORKA's Price Growth Rating (36) in the null industry is in the same range as ENTA (37) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for ORKA (100) in the null industry. This means that ENTA’s stock grew significantly faster than ORKA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAORKA
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
63%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
69%
Advances
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
73%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 10 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
76%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORKA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MPAIX30.93N/A
N/A
Morgan Stanley Inst Advantage I
FNKCX16.74N/A
N/A
Frank Value C
UINQX62.08N/A
N/A
Victory Nasdaq 100 Index Institutional
PXWIX36.70-0.07
-0.19%
Impax Ellevate Global Women's Ldr Instl
MLPEX7.21-0.12
-1.64%
Invesco SteelPath MLP Select 40 C

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with MRUS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then MRUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+1.42%
MRUS - ENTA
50%
Loosely correlated
+0.21%
ORKA - ENTA
37%
Loosely correlated
+12.98%
AKRO - ENTA
35%
Loosely correlated
+16.33%
VRDN - ENTA
34%
Loosely correlated
+2.11%
ANAB - ENTA
34%
Loosely correlated
-0.19%
More

ORKA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORKA
1D Price
Change %
ORKA100%
+12.98%
SYRE - ORKA
50%
Loosely correlated
+19.74%
ATXS - ORKA
46%
Loosely correlated
+0.60%
EYPT - ORKA
46%
Loosely correlated
+0.68%
ELVN - ORKA
45%
Loosely correlated
+4.77%
TRDA - ORKA
45%
Loosely correlated
+10.23%
More